Stereotaxis has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions.
“Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures,” said David Fischel, chairman and chief executive officer (CEO) of Stereotaxis. “By combining our complementary robotic mechanisms, we are creating a uniquely capable platform that expands our reach across interventional medicine. This transaction accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies, opens new avenues for growth, and supports other strategic opportunities being pursued by Stereotaxis.”
Robocath—headquartered in Rouen, France—has developed what it describes as the most advanced mechanical robotic technology for interventional cardiology and neurointerventions. Its flagship R-One+ system is also said to be the only commercially available robotic solution currently available for percutaneous coronary interventions (PCIs) in Europe, with 15 commercial R-One+ systems installed globally.
Robocath is developing a next-generation system designed to enable simultaneous manipulation of up to five interventional devices. Initial first-in-human procedures were recently successfully completed in France. Robocath says its differentiated technologies are supported by a robust intellectual property portfolio.
“For over 15 years, we have been committed to pioneering the most sophisticated plug-and-play bionic robotic technology for endovascular procedures,” commented Robocath founder and CEO Philippe Bencteux. “Joining Stereotaxis provides the scale, complementary technologies and strategic alignment needed to accelerate our development, and expand our impact. We believe this combination will unlock significant opportunities in rapidly growing markets, which are becoming increasingly receptive to robotics.”
Stereotaxis plans to accelerate the development of Robocath’s next-generation system, and pursue regulatory submissions in the USA and Europe within the next two years.
Stereotaxis also says it will enhance Robocath’s system with existing proprietary hardware and software embedded within GenesisX, Synchrony and SynX, enabling advanced functionality including operating room integration, automation, and remote procedures. The combined platform will integrate the robotic systems of Robocath and Stereotaxis to offer a joint solution in interventional cardiology and neurointerventions, while future developments are expected to expand applications into electrophysiology as well.
Stereotaxis estimates that Robocath will contribute approximately US$2 million in annual revenue during the first year post-acquisition, and the acquisition is expected to become breakeven by the third year post-acquisition, supported by commercial and operational synergies.
The transaction consideration includes an upfront payment of US$20 million, and additional contingent payments of up to US$25 million tied to regulatory and commercial milestones, including US Food and Drug Administration (FDA) clearance of Robocath’s next-generation system. Consideration is payable in cash or Stereotaxis common stock, at Stereotaxis’ discretion. The acquisition is subject to customary closing conditions and is expected to close in mid-2026. Upon closing, Robocath will operate as a wholly owned subsidiary of Stereotaxis.
“We are delighted to welcome the accomplished Robocath team to Stereotaxis,” Fischel added. “This acquisition is a reflection of our commitment to technological leadership across endovascular robotics, with continued investment in significant innovations that improve access, efficiency and outcomes of minimally invasive cardiovascular and neurovascular therapies.”
